Reply to: “Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything” and “More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations”

Reply to: “Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything” and “More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations”

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Hepatology - Volume 68, Issue 1, January 2018, Pages 219-220

Lauren A. Beste, Pamela K. Green, Kristin Berry, Matthew J. Kogut, Stephen K. Allison, George N. Ioannou,